- Home
- LDTC vs EVAX Comparison
LDTC vs EVAX Comparison
Compare LDTC & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- EVAX
- Stock Information
- Founded
- LDTC 2007
- EVAX 2008
- Country
- LDTC Canada
- EVAX Denmark
- Employees
- LDTC N/A
- EVAX N/A
- Industry
- LDTC Blank Checks
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDTC Finance
- EVAX Health Care
- Exchange
- LDTC Nasdaq
- EVAX Nasdaq
- Market Cap
- LDTC 10.6M
- EVAX 8.7M
- IPO Year
- LDTC N/A
- EVAX 2021
- Fundamental
- Price
- LDTC $1.17
- EVAX $3.09
- Analyst Decision
- LDTC Buy
- EVAX Strong Buy
- Analyst Count
- LDTC 2
- EVAX 2
- Target Price
- LDTC $3.00
- EVAX $11.00
- AVG Volume (30 Days)
- LDTC 2.8M
- EVAX 234.6K
- Earning Date
- LDTC 12-18-2024
- EVAX 10-31-2024
- Dividend Yield
- LDTC N/A
- EVAX N/A
- EPS Growth
- LDTC N/A
- EVAX N/A
- EPS
- LDTC N/A
- EVAX N/A
- Revenue
- LDTC $353,686.00
- EVAX $3,295,000.00
- Revenue This Year
- LDTC $1,296.78
- EVAX $4,845.21
- Revenue Next Year
- LDTC $137.49
- EVAX $30.30
- P/E Ratio
- LDTC N/A
- EVAX N/A
- Revenue Growth
- LDTC 141.86
- EVAX N/A
- 52 Week Low
- LDTC $0.22
- EVAX $3.05
- 52 Week High
- LDTC $4.98
- EVAX $68.05
- Technical
- Relative Strength Index (RSI)
- LDTC 50.69
- EVAX 26.28
- Support Level
- LDTC $1.27
- EVAX $3.17
- Resistance Level
- LDTC $1.28
- EVAX $3.90
- Average True Range (ATR)
- LDTC 0.26
- EVAX 0.58
- MACD
- LDTC -0.06
- EVAX 0.02
- Stochastic Oscillator
- LDTC 14.85
- EVAX 1.31
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.